Binding of heparan sulfate to human cystatin C modulates inhibition of cathepsin L: Putative consequences in mucopolysaccharidosis.


Journal

Carbohydrate polymers
ISSN: 1879-1344
Titre abrégé: Carbohydr Polym
Pays: England
ID NLM: 8307156

Informations de publication

Date de publication:
01 Oct 2022
Historique:
received: 20 04 2022
revised: 30 05 2022
accepted: 11 06 2022
entrez: 7 7 2022
pubmed: 8 7 2022
medline: 12 7 2022
Statut: ppublish

Résumé

Mucopolysaccharidoses (MPS) are a group of rare lysosomal storage diseases characterized by glycosaminoglycan (GAG) accumulation causing progressive multi-organs dysfunction and ultimately severe cardio-respiratory damages. Human cystatin C (hCC), a potent inhibitor of cysteine cathepsins, plays an important role in respiratory diseases. However, its regulation remained unknown in MPS. Herein, elevated hCC levels were measured in respiratory specimens from MPS-I, -II, and -III patients and were significantly correlated with severe respiratory symptoms (rs = 0.7173). Heparan sulfate (HS), a prominent GAG, dampened its inhibitory activity toward cathepsin L in a dose-dependent manner. HS and HS-oligosaccharides bound tightly hCC, in combination with a secondary structure rearrangement. Molecular modeling studies identified three HS binding regions in hCC, including the N-terminus, which is crucial in the inhibition of cathepsins. Impairment of inhibitory potential of hCC may reflect abnormal regulation of proteolytic activity of cathepsin L in lung, ultimately contributing to the severity of MPS.

Identifiants

pubmed: 35798429
pii: S0144-8617(22)00639-7
doi: 10.1016/j.carbpol.2022.119734
pii:
doi:

Substances chimiques

Cystatin C 0
Glycosaminoglycans 0
Heparitin Sulfate 9050-30-0
Cathepsin L EC 3.4.22.15

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119734

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Sophie Denamur (S)

University Tours, Tours, France; INSERM, UMR 1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Team "Mécanismes protéolytiques dans l'inflammation", Tours, France; Pediatric Department, Reference Center for Inborn Errors of Metabolism ToTeM, CHRU Tours, France. Electronic address: sophie.denamur@univ-tours.fr.

Thibault Chazeirat (T)

University Tours, Tours, France; INSERM, UMR 1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Team "Mécanismes protéolytiques dans l'inflammation", Tours, France. Electronic address: thibault.chazeirat@etu.univ-tours.fr.

Martyna Maszota-Zieleniak (M)

Faculty of Chemistry, University of Gdańsk, Poland.

Romain R Vivès (RR)

University Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France. Electronic address: romain.vives@ibs.fr.

Ahlame Saidi (A)

University Tours, Tours, France; INSERM, UMR 1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Team "Mécanismes protéolytiques dans l'inflammation", Tours, France. Electronic address: ahlame.saidi@univ-tours.fr.

Fuming Zhang (F)

Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, USA.. Electronic address: zhangf2@rpi.edu.

Robert J Linhardt (RJ)

Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, USA.. Electronic address: linhar@rpi.edu.

François Labarthe (F)

Pediatric Department, Reference Center for Inborn Errors of Metabolism ToTeM, CHRU Tours, France; INSERM, UMR 1069, Nutrition, Croissance et Cancer (N2C), Tours, France.. Electronic address: francois.labarthe@univ-tours.fr.

Sergey A Samsonov (SA)

Faculty of Chemistry, University of Gdańsk, Poland. Electronic address: sergey.samsonov@ug.edu.pl.

Gilles Lalmanach (G)

University Tours, Tours, France; INSERM, UMR 1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Team "Mécanismes protéolytiques dans l'inflammation", Tours, France. Electronic address: gilles.lalmanach@univ-tours.fr.

Fabien Lecaille (F)

University Tours, Tours, France; INSERM, UMR 1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Team "Mécanismes protéolytiques dans l'inflammation", Tours, France. Electronic address: fabien.lecaille@univ-tours.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH